Convergent Genomics
Convergent Genomics is a privately held genomic liquid biopsy company developing UroAmp, a non-invasive urine-based DNA sequencing test for early detection and monitoring of urothelial (bladder) cancer recurrence, serving urology practices, academic medical centers, and biopharmaceutical partners through its CLIA-certified laboratory.
- Company typePrivate
- Founded2015
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Convergent Genomics does
Convergent Genomics is a privately held genomic liquid biopsy company founded in 2015 and headquartered in South San Francisco, California. The company developed UroAmp MRD, a non-invasive genomic urine test that uses next-generation DNA sequencing combined with machine learning algorithms to detect, monitor, and predict the risk of urothelial (bladder) cancer recurrence. The test interrogates 60 high-impact urothelial cancer genes while broadly measuring changes across the full genome, producing 15 billion measurements per sample across 250,000 genomic locations to identify six mutation types. Proprietary Enhanced Preservation Media (EPM) stabilizes urine DNA for up to 14 days at room temperature, enabling home or in-clinic sample collection without cold-chain logistics. Clinical validation leveraged the prospective Golestan Cohort Study with urine samples from over 50,000 patients collected up to 12 years ago, supporting reported performance of 92% sensitivity for tumor mutations, 94% specificity, and predictive capability up to 12 years before clinical diagnosis.
The company operates a CLIA-certified (CLIA # 05D2220749), CAP-accredited (# 9512563), and California Department of Public Health certified laboratory. The primary customer segments are urology practices and academic medical centers conducting bladder cancer surveillance and treatment decisions, with a secondary channel targeting biopharmaceutical companies for companion diagnostics and clinical trial support services including trial design, patient identification, and response measurement. The product is currently in limited release since 2021, available for research and select beta sites only, with pricing not publicly disclosed. Revenue is generated through Laboratory Developed Test (LDT) services under FDA enforcement discretion, though specific revenue figures are not disclosed.
Convergent Genomics was founded in partnership with Oregon Health & Science University (OHSU) and Illumina Accelerator, and has received multiple Small Business Innovation Research (SBIR) grants from the National Cancer Institute. The company maintains a research network with over 30 sites worldwide and has published studies in Clinical Cancer Research, Journal of Clinical Medicine, and presented at major urology conferences including the American Urological Association Annual Meeting and European Association of Urology congress.
Convergent Genomics firmographics
Firmographics- Name
- Convergent Genomics
- Legal name
- Convergent Genomics, Inc.
- Website
- https://convergentgenomics.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Convergent Genomics is a privately held genomic liquid biopsy company developing UroAmp, a non-invasive urine-based DNA sequencing test for early detection and monitoring of urothelial (bladder) cancer recurrence, serving urology practices, academic medical centers, and biopharmaceutical partners through its CLIA-certified laboratory.
- Ownership category
- akta.pro rank
Convergent Genomics industry classification
Industry- Product category
- Genomic Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)
- akta.pro secondary industries
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)
Keywords
Where Convergent Genomics is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Convergent Genomics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Laboratory Developed Test (LDT) Services: Convergent Genomics operates a CLIA-certified and CAP-accredited laboratory that performs the UroAmp genomic urine test. The test is classified as a laboratory-developed test under FDA enforcement discretion. Revenue is generated through laboratory testing services billed to healthcare providers, insurance, or directly to patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Laboratory testing service for bladder cancer MRD detection |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Convergent Genomics product offering
Product offeringCore offering
Convergent Genomics provides UroAmp MRD, a non-invasive laboratory developed genomic urine test that detects, monitors, and predicts the risk of urothelial (bladder) cancer or its recurrence using ultra-deep next-generation DNA sequencing and machine learning. The test is performed at the company's CLIA-certified and CAP-accredited laboratory in South San Francisco and is currently available in limited release for research and select beta sites only.
Product overview
Convergent Genomics offers a single unified product: UroAmp MRD, a non-invasive genomic urine test for bladder cancer detection, monitoring, and risk prediction. The product uses next-generation DNA sequencing combined with machine learning algorithms to analyze urine samples, interrogating 60 high-impact urothelial cancer genes while measuring changes across the full genome. UroAmp MRD provides a Positive or Negative output along with a genomic disease burden (GDB) score and tumor grade prediction to help monitor disease progression, recurrence, and response to therapeutic interventions. The company also developed Enhanced Preservation Media (EPM) to stabilize DNA in urine samples for up to 14 days at room temperature, supporting the test's home collection capability.
Differentiator
Problem solved
Functional benefit
Products and services
- UroAmp MRD A non-invasive genomic urine test that detects, monitors, and predicts the risk of urothelial cancer or its recurrence well before signs and symptoms develop. The test deeply interrogates 60 of the most high-impact urothelial cancer genes while broadly measuring changes across the whole genome, validated to determine minimal residual disease (MRD) in patients with bladder cancer history. It provides a Positive or Negative output along with a genomic disease burden (GDB) score and tumor grade prediction.
Quantifiable outcome
- 92% sensitivity in detecting tumor mutations from urine DNA
- +5 more outcomes
Companies that use Convergent Genomics
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Convergent Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Convergent Genomics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Photocure ASAcorePhotocure ASA announced a clinical trial at the 2026 European Association of Urology congress comparing minimal residual disease outcomes between blue light and white light cystoscopy using Convergent Genomics' UroAmp biomarker. The CUT-less trial (327 patients) examines MRI staging combined with blue light cystoscopy, with a second trial (200 subjects) using UroAmp for comparison. This represents a clinical validation partnership for bladder cancer diagnostic pathways.
- Oregon Health & Science University (OHSU)coreConvergent Genomics was founded in 2015 in partnership with Oregon Health & Science University (OHSU) and Illumina Accelerator. The company originated from academic research collaboration in cancer genomics with OHSU researchers.
- Illumina AcceleratorcoreConvergent Genomics was founded in 2015 in partnership with Oregon Health & Science University (OHSU) and Illumina Accelerator. Illumina Accelerator is the company's founding partner providing sequencing technology and startup ecosystem support.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Convergent Genomics competitors and assessment
Company assessmentDirect peers
- Pacific Edge Diagnostics: Pacific Edge's Cxbladder is a urine-based molecular diagnostic for detecting and monitoring bladder cancer, the most directly comparable product to UroAmp in terms of sample type, indication, and clinical use case.
- Natera: Natera's Signatera is a leading tumor-informed MRD test used across solid tumors; it competes with UroAmp in MRD monitoring and shares a similar molecular residual disease detection thesis applied to oncology surveillance.
Broad incumbents
- Guardant Health: Guardant Health is an established liquid biopsy leader with Guardant360 and Reveal MRD; it operates in the same oncology liquid biopsy category with substantially broader indication coverage and commercial scale.
- NeoGenomics: NeoGenomics provides oncology-focused molecular and genetic testing services, including liquid biopsy, and competes with Convergent for hospital and urology practice send-out volume.
- Foundation Medicine: Foundation Medicine offers comprehensive genomic profiling for solid tumors; while tissue-based, it overlaps with UroAmp in guiding targeted therapy selection (e.g., erdafitinib, pembrolizumab) in bladder cancer.
- Exact Sciences: Exact Sciences is a major molecular diagnostics company with a urine/stool-based screening franchise (Cologuard); its commercial scale and R&D pipeline make it a comparable diagnostics platform peer.
- Caris Life Sciences: Caris provides molecular profiling and AI-driven analytics across oncology indications; it competes with Convergent in comprehensive tumor profiling and biopharma partnership opportunities.
Emerging players
- Personalis: Personalis offers ultra-sensitive cancer genomics for MRD and immunotherapy monitoring; its NeXT Personal test competes with Convergent's MRD positioning and shares a deep-sequencing technical approach.
- Tempus: Tempus applies AI-driven multi-omics to oncology and biopharma decision support; it overlaps with Convergent's machine-learning-driven genomic interpretation and biopharma service model.
Others
- Bio-Techne: Bio-Techne supplies reagents, assays, and exosome-based liquid biopsy research tools used by diagnostic developers; it is comparable as an enabling life-science tools vendor rather than a direct diagnostic competitor.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Convergent Genomics social profiles
Digital presenceConvergent Genomics compliance and trust
Trust signalCompliance3 records
Convergent Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Convergent Genomics leadership team
Management profileNumber of profiles
Profiles10 records
Convergent Genomics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Convergent Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Convergent Genomics
What does Convergent Genomics do?
Convergent Genomics provides UroAmp MRD, a non-invasive laboratory developed genomic urine test that detects, monitors, and predicts the risk of urothelial (bladder) cancer or its recurrence using ultra-deep next-generation DNA sequencing and machine learning. The test is performed at the company's CLIA-certified and CAP-accredited laboratory in South San Francisco and is currently available in limited release for research and select beta sites only.
Is Convergent Genomics a public or private company?
Convergent Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Convergent Genomics founded?
Convergent Genomics was founded in 2015. It employs 11 to 50 people.
Where is Convergent Genomics based?
Convergent Genomics is headquartered in San Francisco, United States, in the North America region.
How does Convergent Genomics make money?
One revenue line is on record: laboratory Developed Test (LDT) Services.
Who are Convergent Genomics's main competitors?
Direct peers on record are Pacific Edge Diagnostics and Natera. Broad incumbents are Guardant Health, NeoGenomics, Foundation Medicine, Exact Sciences and Caris Life Sciences. Emerging players are Personalis and Tempus. Bio-Techne is listed as an others.
Does Convergent Genomics have an API?
No public API is recorded for Convergent Genomics.
What industry is Convergent Genomics in?
Convergent Genomics's product category is Genomic Cancer Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 621511 and its SIC code is 8071.